Showing results for:
Pegfilgrastim is FDA approved toDecrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome).Limitations of Use: Pegfilgrastim is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation
Neulasta® Pegfilgrastim G-CSF Fulphila™ * Pegfilgrastim-jmdb* Udenyca™ * Pegfilgrastim-cbqv* Ziextenzo™ * Pegfilgrastim-bmez * Nyvepria Pegfilgrastim-apgf* Fylnetra* Pegfilgrastim-pbbk* Stimufend®* Pegfilgrastim-fpgk*